Renaissance Technologies (RenTech)'s AQST Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 416,248 shares of Aquestive Therapeutics, Inc. (AQST) worth $1.73 M, representing 0.00% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in AQST, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 1.19 M shares. Largest reduction occurred in Q2 2024, reducing 879,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Aquestive Therapeutics (AQST) Holding Value Over Time
Track share changes against reported price movement
Quarterly Aquestive Therapeutics (AQST) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +416,248 | New Buy | 416,248 | $4.16 |
| Q1 2026 | -414,400 | Sold Out | 0 | $0.00 |
| Q4 2025 | +327,400 | Add 376.32% | 414,400 | $6.46 |
| Q3 2025 | +87,000 | New Buy | 87,000 | $5.59 |
| Q1 2025 | -95,400 | Sold Out | 0 | $0.00 |
| Q4 2024 | +66,800 | Add 233.57% | 95,400 | $3.56 |
| Q3 2024 | -467,600 | Reduce 94.24% | 28,600 | $4.98 |
| Q2 2024 | -879,600 | Reduce 63.93% | 496,200 | $2.60 |
| Q1 2024 | +104,300 | Add 8.20% | 1.38 M | $4.26 |
| Q4 2023 | +142,311 | Add 12.60% | 1.27 M | $2.02 |
| Q3 2023 | -101,007 | Reduce 8.21% | 1.13 M | $1.53 |
| Q2 2023 | +711,396 | Add 137.12% | 1.23 M | $0.00 |
| Q1 2023 | +56,063 | Add 12.12% | 518,800 | $0.00 |
| Q4 2022 | -438,063 | Reduce 48.63% | 462,737 | $0.00 |
| Q3 2022 | -325,600 | Reduce 26.55% | 900,800 | $1.17 |
| Q2 2022 | +1.19 M | Add 3475.51% | 1.23 M | $0.64 |
| Q1 2022 | +23,043 | Add 204.70% | 34,300 | $2.62 |
| Q4 2021 | -178,412 | Reduce 94.06% | 11,257 | $3.91 |
| Q3 2021 | -55,779 | Reduce 22.73% | 189,669 | $4.36 |
| Q2 2021 | +245,448 | New Buy | 245,448 | $3.97 |
| Q1 2021 | -271,800 | Sold Out | 0 | $0.00 |
| Q4 2020 | +271,800 | New Buy | 271,800 | $5.35 |
| Q2 2020 | -294,051 | Sold Out | 0 | $0.00 |
| Q1 2020 | +215,051 | Add 272.22% | 294,051 | $2.19 |
| Q4 2019 | +79,000 | New Buy | 79,000 | $5.82 |
Renaissance Technologies (RenTech)'s Aquestive Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Aquestive Therapeutics, Inc. (AQST) in Q4 2019, acquiring 79,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Aquestive Therapeutics, Inc. (AQST) for 25 quarters since Q4 2019.
Renaissance Technologies (RenTech)'s largest addition to Aquestive Therapeutics, Inc. (AQST) was in Q2 2022, adding 1,226,400 shares worth $785,000.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 416,248 shares of Aquestive Therapeutics, Inc. (AQST), valued at approximately $1.73 M.
As of the Q2 2026 filing, Aquestive Therapeutics, Inc. (AQST) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Aquestive Therapeutics, Inc. (AQST) was 1,375,800 shares, as reported at the end of Q1 2024.